IPQ Inside the global regulatory dialogue

Novel Excipients, DMFs, and Atypical Actives Among Pressing Issues on IPEC-Americas’ Front Burner

Aug 29th, 2018

Please Log in to print the full article

IPEC-Americas followed up on the appointment by providing Hennessey with “a pretty extensive list” of areas where it is currently working and would like close cooperation with FDA to take place. Novel excipients, Zawislak stressed,...

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2021 IPQ Publications